REG - Eden Research plc - Mevalone Approval in California - Powdery Mildew

Eden ResearchAnnouncement

Today 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250513:nRSM3471Ia&default-theme=true

RNS Number : 3471I  Eden Research plc  13 May 2025

The information contained within this announcement is deemed to constitute
inside information as stipulated under the retained EU law version of the
Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK
law by virtue of the European Union (Withdrawal) Act 2018. The information is
disclosed in accordance with the Company's obligations under Article 17 of the
UK MAR. Upon the publication of this announcement, this inside information is
now considered to be in the public domain.

 

13 May 2025

 

 

Eden Research plc

("Eden" or "the Company")

 

 

Approval of Mevalone® to control powdery mildew in Californian grapes

 

 

Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and
biocontrol technology, is pleased to announce the approval of its flagship
product, the fungicide Mevalone®, for the control of powdery mildew in grapes
in California. This latest regulatory approval extends the use of Mevalone on
grapes in California, where it is already approved for the control of Botrytis
cinerea.

 

Sipcam Agro USA, which already acts as the Company's exclusive distributor for
Mevalone in the US, will now actively promote Mevalone for this new use,
providing even more versatility for growers. It is expected that the label and
marketing materials detailing the use of Mevalone for the control of powdery
mildew will be updated for the current growing season. While the Company
believes that the inclusion of powdery mildew to the label adds to the
applicability of Mevalone for farmers and increases the chance of achieving a
greater market share among botryticides, it does not expect to change its
revenue expectations in the near term.

 

Powdery mildew is a fungal disease that affects many crops. Eden estimates
that the total addressable market for Mevalone in the US is in the region of
€94 million, with California representing the largest share of this
potential by a substantial margin.

 

California leads US grape production, and powdery mildew and Botrytis severely
impact California grape production, with the former representing the most
prevalent fungal disease affecting grapes. Eden's solution not only provides a
residue-free, plant-based option to vineyard managers but also represents an
effective tool when compared to its conventional alternatives.

 

Sean Smith, Chief Executive Officer of Eden Research, commented:

 

"This approval in the leading US grape production state shows Eden's
commitment to supporting sustainable agriculture across regions with the
highest standards of efficacy, quality and safety. California's grape growers
can now use Mevalone with protocols and application methods similar to those
in Italy or Spain, where powdery mildew significantly impacts grape production
and quality. With this regulatory approval, Eden expands the potential for
Mevalone in the US."

 

Brent Marek, CEO of Sipcam Agro USA, commented:

 

"Speaking to grape growers across California, Botrytis and powdery mildew are
without question two of the most critical diseases affecting production in
California. With today's approval, growers are now afforded a better and more
effective tool to manage powdery mildew with a novel mode of action that is
well recognised by experts in agronomy and fungicide resistance in many other
countries. We're also pleased this approval has arrived in time for the start
of the 2025 season. Sipcam Agro USA has a strong commitment to the success of
the product, as reflected in the considerable marketing resources we've
allocated to this product."

 

 

-- ENDS --

 

 

For further information contact:

 

 Eden Research plc
 Sean Smith                                            www.edenresearch.com (http://www.edenresearch.com/)

Alex Abrey

                                                       01285 359 555

 Cavendish Capital Markets Limited

(Nominated advisor and joint broker)
 Giles Balleny / George Lawson (corporate finance)     020 7220 0500

Charlie Combe (corporate broking)

Michael Johnson (sales)

 Oberon Capital (Joint broker)
 Nick Lovering                                         020 3179 5300

 Mike Seabrook

 Adam Pollock

 Hawthorn Advisors (Financial PR)
 Victoria Ainsworth                                    eden@hawthornadvisors.com

 

 

Notes to Editors:

 

Eden Research is the only UK-listed company focused on biopesticides for
sustainable agriculture. It develops and supplies innovative biopesticide
products and natural microencapsulation technologies to the global crop
protection, animal health and consumer products industries.

 

Eden's products are formulated with terpene active ingredients, based on
natural plant defence metabolites. To date, they have been primarily used on
high-value fruits and vegetables, improving crop yields and marketability,
with equal or better performance when compared with conventional pesticides.
Eden has three products currently on the market:

 

Based on plant-derived active ingredients, Mevalone(®) is a foliar
biofungicide which initially targets a key disease affecting grapes and other
high-value fruit and vegetable crops.  It is a useful tool in crop defence
programmes and is aligned with the requirements of integrated pest management
programmes. It is approved for sale in a number of key countries whilst Eden
and its partners pursue regulatory clearance in new territories thereby
growing Eden's addressable market globally.

 

Novellus®+ is an evolution of Mevalone, allowing improved rates in the
field, high levels of efficacy and a broader list of targets.

 

Cedroz™( )is a bionematicide that targets free living nematodes which are
parasitic worms that affect a wide range of high-value fruit and vegetable
crops globally.  Cedroz is registered for sale on two continents and Eden's
commercial collaborator, Eastman Chemical, is pursuing registration and
commercialisation of this important new product in numerous countries
globally.

 

Eden's seed treatment product, Ecovelex™ was developed to safely tackle
crop destruction caused by birds - a major cause of losses in maize and other
crops. Ecovelex works by creating an unpleasant taste or odour that repels
birds, leaving the seeds safely intact and the birds unaffected and free to
find alternative food sources. The product is based on Eden's plant-derived
chemistry, registered in the EU, US and elsewhere, and formulated using Eden's
Sustaine(®) microencapsulation system.

 

Eden's Sustaine(®)( )encapsulation technology is used to harness the
biocidal efficacy of naturally occurring chemicals produced by plants
(terpenes) and can also be used with both natural and synthetic compounds to
enhance their performance and ease of use. Sustaine microcapsules are
naturally-derived, plastic-free, biodegradable micro-spheres derived from
yeast. It is one of the only viable, proven and immediately registerable
solutions to the microplastics problem in formulations requiring
encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the
symbol EDEN. It was awarded the London Stock Exchange Green Economy
Mark in January 2021, which recognises London-listed companies that derive
over 50% of their total annual revenue from products and services that
contribute to the global green economy. Eden derives 100% of its total annual
revenues from sustainable products and services.

 

For more information about Eden, please visit: www.edenresearch.com
(http://www.edenresearch.com/) . You can also follow Eden's latest
developments via its social media channels: X (Twitter)
(https://twitter.com/edenresearch)  and LinkedIn
(https://www.linkedin.com/company/eden-research-plc/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  REAKLLFFEELBBBQ